• Special Issue Topic

    Immunotherapy in Cancer Patients

    Submission Deadline: September 30, 2020

    Guest Editor

    Prof. Rossana Berardi E-Mail

    Professor in Medical Oncology and Director of the Postgraduate School of Medical Oncology at Università Politecnica Marche; Director of Department of Medical Oncology, Director of “Genetic Cancer” Center and Breast Unit Coordinator at Ospedali Riuniti of Ancona, Italy

    Research Keywords: thoracic cancer; breast cancer; neuroendocrine tumors; innovative therapies; COVID-19 and cancer

    About the Special Issue

    Immunotherapy in the last years improved outcome of cancer patients, inducing durable tumour responses, in particular in patients affected by NSCLC and melanoma. Immune checkpoint inhibitors regulate and stimulate the immune system to recognize and attack tumour cells. It is commonly better tolerated than chemotherapy and targeted therapy with a unique toxicity profile depending on their different of mechanism of activity.
    These toxicities, despite rare, can be sometimes disabling.
    However, some patients do not benefit from immunotherapy. Several original researches investigated the potential predictive role of clinical, pathological, laboratoristic factors to select responder patients.
    Notwithstanding, a validated predictive parameters do not detected.
    Immunotoxicity could involve all organs and systems requiring a specific management including steroids, immunomodulating therapy in multidisciplinary approach. Pathophysiology of immune-toxicity is still unclear. Parameters potentially associated with increased risk of immune-related adverse events are still under investigation.
    This special issue focus on predictive factors of response and toxicity in cancer patients treated with immunotherapy in order to improve the management of those subjects.

    logo.pngWomen for Oncology – Italy supports this special issue.

    Keywords: immunotherapy; immune-related toxicity; multidisciplinary approach

    Published Articles

    Open Access
    Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
    The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In r [...] Read more.
    Stefano Cavalieri ... Laura D. Locati
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:522–542
    DOI: https://doi.org/10.37349/etat.2021.00062
    Open Access
    Original Article
    Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
    Aim: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of T [...] Read more.
    Edoardo Lenci ... Rossana Berardi
    Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:227–239
    DOI: https://doi.org/10.37349/etat.2021.00043
    Open Access
    Gastrointestinal disorders as immune-related adverse events
    Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel dr [...] Read more.
    Daniele Balducci ... Luca Maroni
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:174–186
    DOI: https://doi.org/10.37349/etat.2021.00039
    Open Access
    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
    Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseas [...] Read more.
    Valeria Cognigni ... Rossana Berardi
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:122–138
    DOI: https://doi.org/10.37349/etat.2021.00036
    Open Access
    Immunotherapy in gynecological cancers
    Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to e [...] Read more.
    Domenica Lorusso ... Giovanni Scambia
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:48–64
    DOI: https://doi.org/10.37349/etat.2021.00033
    Times Cited: 0
    Open Access
    Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
    The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in p [...] Read more.
    Luca Cantini ... Rossana Berardi
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:1–25
    DOI: https://doi.org/10.37349/etat.2021.00030
    Times Cited: 0
    Open Access
    Letter to the Editor
    Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particula [...] Read more.
    Marta Brambilla ... Mario Occhipinti
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427–433
    DOI: https://doi.org/10.37349/etat.2020.00027
    Open Access
    An overview of immune checkpoint inhibitors in breast cancer
    Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-nega [...] Read more.
    Federica Miglietta ... Nicla La Verde
    Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452–472
    DOI: https://doi.org/10.37349/etat.2020.00029
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c [...] Read more.
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372–380
    DOI: https://doi.org/10.37349/etat.2020.00022
    Times Cited: 0